RESEARCH AND EDUCATION DISCLAIMER
This article summarizes published scientific research for educational purposes only. Level Up Peptides products are intended exclusively for laboratory research by qualified researchers and are not for human or veterinary use. Discussion of published animal or human studies does not recommend those uses or establish the safety or effectiveness of any product sold on this website. This article does not provide medical advice, dosing guidance, or administration instructions.
SUMMARY
AOD-9604 is a synthetic peptide investigated in fat-metabolism research, human obesity trials, and an experimental cartilage model. Early animal studies reported changes in bodyweight and fat metabolism, but the larger human obesity trial did not demonstrate a statistically significant weight-loss benefit over placebo. A separate publication summarized human safety observations. These different findings need to be considered together: an experimental biological effect, a tolerability observation, and a demonstrated clinical benefit are not interchangeable. [1–5]
WHAT IS AOD-9604?
AOD-9604 is a 16-amino-acid peptide based on a small section near the end of human growth hormone, with an added terminal tyrosine. It is a distinct molecule from full-length growth hormone. Researchers developed it to investigate whether selected metabolic effects could be separated from other growth-hormone actions. [1]
Its relationship to growth hormone does not establish that it has the same effects, risks, or applications. Those questions require evidence specific to AOD-9604.
WHAT DID THE EARLY RAT STUDY FIND?
A study published in 2000 examined AOD-9604 in obese Zucker rats over 19 days. Treated animals gained less bodyweight than controls, and their fat tissue showed increased lipolytic activity, meaning increased breakdown of stored fat. [2]
The wording matters: the animals gained less weight. That result should not be rewritten as an equivalent amount of weight loss. It also describes a particular animal model over a short period, rather than an established outcome in people.
WHAT DID THE MOUSE STUDY ADD?
A 2001 study examined obese mice and mice lacking beta-3 adrenergic receptors, which participate in fat-cell signaling. AOD-9604 reduced bodyweight and body fat in the obese-mouse experiments and changed expression of this receptor. [3]
However, the results did not support a simple explanation that AOD-9604 acts directly through that receptor alone. Some acute metabolic responses remained in mice lacking it. The study therefore raised questions about how different pathways contribute to the observed effects, rather than establishing one complete mechanism. [3]
WHAT HAPPENED IN THE HUMAN WEIGHT-LOSS TRIAL?
The larger phase 2b study, known as METAOD006 or OPTIONS, randomized 502 adults with obesity to oral AOD-9604 or placebo. Participants also followed a diet and exercise program. [1,4]
In February 2007, the developer reported that differences in weight loss between AOD-9604 and placebo were not statistically significant at either the 12-week primary endpoint or the 24-week secondary endpoint. The company consequently ended development for obesity. These results were disclosed in a sponsor announcement, which should be distinguished from a full peer-reviewed efficacy report. [4]
This negative result is central to interpreting the earlier animal findings. The human trial did not establish AOD-9604 as an effective weight-loss treatment under the conditions tested. A different formulation or route would need its own evidence; it cannot be assumed to overcome an unsuccessful trial.
WHAT DOES THE HUMAN SAFETY PUBLICATION SHOW?
A 2013 paper summarized safety and tolerability observations from six placebo-controlled studies. The authors reported no significant increases in circulating IGF-1, a growth-related signaling protein, and generally comparable adverse-event patterns between treatment and placebo groups. [1]
The studies included short intravenous investigations and longer oral studies. Their findings should not be generalized to every formulation, route, or duration. Favorable observations in selected measurements also do not establish an absence of uncommon or long-term risks, and tolerability does not demonstrate effectiveness. [1]
HAS AOD-9604 BEEN STUDIED IN CARTILAGE RESEARCH?
A 2015 study examined 32 rabbits with experimentally induced knee osteoarthritis. Researchers compared saline, hyaluronic acid, AOD-9604, and a combination of AOD-9604 with hyaluronic acid. Cartilage assessments favored the active-treatment groups over saline, with the combination producing the most favorable scores. [5]
These findings concern an induced rabbit disease model. They do not establish cartilage regeneration, pain relief, or improved joint function in people. They also do not validate claims about tendon repair or general injury recovery.
WHAT REMAINS UNCERTAIN?
The research leaves unresolved questions about mechanisms, reproducibility, and whether any specific application can produce meaningful clinical benefits. Animal results need confirmation in appropriately designed human studies, while negative clinical findings must remain part of the assessment.
For laboratory work, the material being tested must be clearly identified and characterized. A published study does not verify the identity, purity, stability, or activity of a separately supplied research product. Those properties require material-specific documentation and testing.
REFERENCES
Some study titles are shortened for readability. Each link identifies the original source.
[1] Stier H, Vos E, Kenley D. Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans. Journal of Endocrinology and Metabolism. 2013;3(1–2):7–15.
https://doi.org/10.4021/jem157w
[2] Ng FM, Sun J, Sharma L, et al. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Hormone Research. 2000;53(6):274–278.
https://doi.org/10.1159/000053183
[3] Heffernan M, Summers RJ, Thorburn A, et al. Human growth hormone and AOD9604: lipid-metabolism experiments in obese and beta-3 receptor knockout mice. Endocrinology. 2001;142(12):5182–5189.
https://doi.org/10.1210/endo.142.12.8522
[4] Metabolic Pharmaceuticals Limited. Metabolic’s obesity drug—Phase 2B clinical trial results. ASX announcement, February 21, 2007. Original sponsor disclosure; not a peer-reviewed journal article.
https://announcements.asx.com.au/asxpdf/20070221/pdf/3111t0ww55jr72.pdf
[5] Kwon DR, Park GY. Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model. Annals of Clinical and Laboratory Science. 2015;45(4):426–432.